BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
TEL AVIV, Israel, August 29, 2016 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City.
The BioLineRx presentation is scheduled to start at 3:50 p.m. EDT on Monday, September 12, 2016. A live audio webcast of the presentation will be available online at the investor page of the Company's website. An archive of the event will also be available for those unable to listen live.
In addition, any investors attending the conference that wish to meet with Mr. Serlin for a one-on-one meeting should contact Lily Khaykina at [email protected].
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment, and has recently initiated a Phase 2 study in stem cell mobilization for allogeneic transplantation; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently signed a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA®.
For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com , where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
[email protected]
or
Tsipi Haitovsky
Public Relations
+972-3-624-0871
[email protected]
SOURCE BioLineRx Ltd.
Share this article